• Cell & Gene therapy manufacturing congress
    • Christopher Bravery
    • Amsterdam, Netherlands
    • Panellist, trainer & chair



  • 2019 PharmSci 360
    • What’s Different about Potency Assays for Cell and Gene Therapy?
    • Texas, USA
    • Speaker





  • ATMP, are we there yet? 
    • Advanced Therapy Medicinal Products - From Promise to Cure
    • Christopher Bravery
    • Vilnius, Lithuania



  • 2019 Cell Therapy CMC and Manufacturing Europe
    • Christopher Bravery
    • Boston, MA
    • Speaker, chair & workshop



  • Cell therapy Manufacturing Asia
    • Christopher Bravery
    • Tokyo, Japan
    • Pre & Post conference workshops

Product Development

Most cell and gene therapy products are regulated as medicinal products in the EU and the US; as such their development must result in data that confirm quality, safety and efficacy.  
One of the key objectives of
 , aside from demonstration of clinical efficacy, is to fully understand the characteristics of the product and the process used to make it. Characterisation is central to product development, this figure provides an overview of the scope of characterisation activities and how they interrelate.

Effective development processes provide all the tools necessary to implement changes, and these tools are a result of thorough characterisation.  Implementation of changes to the manufacture of medicinal products requires that the product before and after the change is comparable.  Comparability is a central concept in the regulation of medicinal products; this tool provides an overview of the various parameters that might be required for a comparability exercise. 


Regulatory Tools (last update)


Regulatory Guidance (last update)

There are a number of specific guidelines covering the development of ATMP's, however, many more general biological/biotech guidance is also indirectly relevant since they provide the general principle described in ICH documents are harmonised across ICH member countries

Pharmacopoeial chapters with relevance to cell-based medicinal products:

Note: These figures do not include hyperlinks since the content requires subscription.


The Common Technical Document (CTD) (Version 2.1 December 2019)

Now with increased detail including excerpts from ICH guidelines and authors comments and suggestions 


NEW!!  ATMP Standards mapping exercise

With so many organisations writing standards for cell, gene and tissue therapies its easy to lose track of them all.  This is an initial draft map (Dec 2020), please feel free to send details of any standards not yet included.

Note: for pharmacopeia’s, only texts specific to ATMP are included.


NEW in Beta!! Elements of the CoA when selecting materials.

This decision tree is designed to aid evaluation of the certificate of analysis (CoA) of a material to ensure the range of methods included are appropriate.

This is a beta version, so please do provide feedback at info at advbiols.com


Coming soon: decision tree for identifying and mitigating risks associated with raw materials.


Instructions: Many of these tools are interactive and can be expanded or collapsed by clicking on the (+).  Alternatively you can expand or collapse levels by right clicking on the diagram and selecting the required level.  

Links to external documents are included and indicated by the following symbol Simply click to open the document in a new tab.

Some tools contain notes, hover or click on note symbol to see note.



We value your feedback; should you have comments or suggestions for inclusions and amendments please let us know. Contact: info at advbiols.com



These tools were developed with the support of a grant from the Technology Strategy Board as part of the VALUE consortium (Regenerative Medicine Value Systems: Navigating the Uncertainties) lead by Biolatris Ltd (http://www.biolatris.com). 






  • HealthTech and Medicines KTN Regenerative Medicines. US Mission
    • Christopher A, Bravery, PhD.
    • Knowledge Transfer Network.
    • Boston, MA, United States.



  • Panel discussion.
    • Christopher A, Bravery, PhD.
    • ISSCR/CIR/ISCT Workshop: Stem Cell Therapies in Clinical Trials- Best practices and the need of Harmonization.
    • San Francisco, California, United States.












  • "Reference Standards: Regulatory requirements" 
    • Christopher A, Bravery, PhD. 
    • Informa Life Sciences 2nd Annual: Cell Therapy Manufacturing: Stem Cells and Immunotherapies.  
    • Chair, speaker, panel discussion, workshop.
    • Brussels, Belgium



  • Joint DIA/MHRA Workshop on Advanced Therapy Medicinal Products
    • Christopher A, Bravery, PhD. 
    • London, UK
    • Chair, panel discussion









  • "What's happened since Regulation 1394/2007?"  
    • Christopher A, Bravery, PhD.
    • Regenerative Medicine in Europe (REMEDIE): Bringing Regenerative Medicine to the Clinic: Trials and Tribulations in Europe and Beyond.
    • Bilbao, Vizcaya, Spain.



  • Seminar
    • Christopher A, Bravery, PhD.
    • EUCRAF: Particulars of authorisation of biopharmaceuticals.
    • Freiburg, Germany.



  • Workshop on progress towwards Clinical Trials using stem cells for ALS/MND
    • Christopher A, Bravery, PhD.
    • International Consortium of Stem Cell Networks (ICSCN).
    • New York, United States